Gilead Sciences Inc. (NASDAQ:GILD) has voluntarily recalled one lot of its COVID-19 treatment, Veklury (remdesivir), for Injection 100 mg/vial, after discovering glass particles in the vials.
The company received a customer complaint that prompted an investigation, confirming the presence of foreign material in the product.
Gilead is taking necessary measures to ensure the safety of patients and healthcare providers by facilitating the recall process.
The administration of a contaminated injectable could lead to health risks, including local irritation or swelling. If glass particles travel through the bloodstream, they may obstruct blood vessels in vital organs, potentially resulting in strokes or even death.
Gilead has reported no adverse events associated with this recall to date.
Veklury is designed for the treatment of COVID-19 in both adults and pediatric patients, specifically those who are hospitalized or non-hospitalized but at high risk of progression to severe COVID-19.
Its use is restricted to healthcare settings that manage severe reactions, including anaphylaxis.
In 2021, Gilead Sciences issued a nationwide recall of two lots of its COVID-19 treatment drug Remdesivir because they contained glass particulates.
In the second quarter of 2024, Veklury sales decreased 16% year over year to $214 million, primarily due to lower rates of COVID-19-related hospitalizations.
Price Action: GILD stock is down 0.05% at $83.90 at last check Monday.
Image via Unsplash
Read Next:
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
